Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?

Institutional investors are heavily investing in Madrigal Pharmaceuticals (NASDAQ: MDGL) stock, despite the company's stock price falling more than 7% this year. Baker Brothers Advisors, Janus Henderson Group, and RTW Investments all own significant shares of the company, holding over 95% of its float. Madrigal's first commercial drug, Rezdiffra, received FDA approval in 2024 to treat metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease.

Despite competition from Novo Nordisk's Wegovy, Rezdiffra's sales continue to rise, with a 71% increase in the second quarter compared to the same period last year. The global prevalence of MASH is expected to grow significantly by 2050, which could boost Rezdiffra's market share. Madrigal's combination of a unique asset, strong cash reserves, and a promising pipeline makes it an attractive target for larger pharmaceutical companies, potentially leading to a takeover.